Irene Litvan
The paucity of novel drugs for neuropsychiatric indications contrasts with the remarkable recent advances in neuroscience research. We have identified 5 challenges the sector must address and recommend potential solutions. The tools that will allow these solutions to be implemented may already be in place but not routinely adopted or are still being developed. Overall, a change in mind set to adopt science- and data-driven paths is needed
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi